These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18392319)

  • 1. Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor.
    Andreotti F; Santucci E
    Thromb Haemost; 2008 Apr; 99(4):651-2. PubMed ID: 18392319
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
    Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
    Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor Xa inhibitors: today and beyond.
    Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
    Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenyltriazolinones as potent factor Xa inhibitors.
    Quan ML; Pinto DJ; Rossi KA; Sheriff S; Alexander RS; Amparo E; Kish K; Knabb RM; Luettgen JM; Morin P; Smallwood A; Woerner FJ; Wexler RR
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1373-7. PubMed ID: 20100660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anticoagulants based on direct inhibition of thrombin and factor Xa.
    Gardell SJ; Sanderson PE
    Coron Artery Dis; 1998; 9(2-3):75-81. PubMed ID: 9647407
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effects of intravenous injection of sulphated galactomannan on anticoagulant activity of rat plasma].
    Drozd NN; Makarov VA; Tolstenkov AS; Lapikova ES; Miftakhova NT; Mestechkina NM; Shcherbukhin VD; Il'ina AV; Varlamov VP
    Patol Fiziol Eksp Ter; 2008; (3):20-3. PubMed ID: 18946908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro.
    Jiang X; Crain EJ; Luettgen JM; Schumacher WA; Wong PC
    Thromb Haemost; 2009 Apr; 101(4):780-2. PubMed ID: 19350128
    [No Abstract]   [Full Text] [Related]  

  • 9. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
    Furugohri T; Shiozaki Y; Muramatsu S; Honda Y; Matsumoto C; Isobe K; Sugiyama N
    Eur J Pharmacol; 2005 May; 514(1):35-42. PubMed ID: 15878322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches in anticoagulation: rationales for target positioning.
    Wieland HA; Laux V; Kozian D; Lorenz M
    Curr Opin Investig Drugs; 2003 Mar; 4(3):264-71. PubMed ID: 12735227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor Xa inhibitors: next-generation antithrombotic agents.
    Pinto DJ; Smallheer JM; Cheney DL; Knabb RM; Wexler RR
    J Med Chem; 2010 Sep; 53(17):6243-74. PubMed ID: 20503967
    [No Abstract]   [Full Text] [Related]  

  • 13. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.
    Wong PC; Crain EJ; Xin B; Wexler RR; Lam PY; Pinto DJ; Luettgen JM; Knabb RM
    J Thromb Haemost; 2008 May; 6(5):820-9. PubMed ID: 18315548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
    Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic pathway of coagulation and arterial thrombosis.
    Gailani D; Renné T
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2507-13. PubMed ID: 17916770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Quan ML; Han Q; Galemmo RA; Amparo E; Wells B; Ellis C; He MY; Alexander RS; Rossi KA; Smallwood A; Wong PC; Luettgen JM; Rendina AR; Knabb RM; Mersinger L; Kettner C; Bai S; He K; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4141-7. PubMed ID: 16730984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.
    Samama MM; Amiral J; Guinet C; Perzborn E; Depasse F
    Thromb Haemost; 2010 Nov; 104(5):1078-9. PubMed ID: 20806114
    [No Abstract]   [Full Text] [Related]  

  • 19. Protein Z-dependent regulation of coagulation.
    Broze GJ
    Thromb Haemost; 2001 Jul; 86(1):8-13. PubMed ID: 11487045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel constructs for thrombin inhibition.
    Becker RC
    Am Heart J; 2005 Jan; 149(1 Suppl):S61-72. PubMed ID: 15644795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.